Literature DB >> 25047707

Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers.

Agnieszka K Witkiewicz1, Uthra Balaji2, Erik S Knudsen1.   

Abstract

PURPOSE: We sought to systematically define determinants of the response to neoadjuvant chemotherapy to elucidate predictive biomarkers for breast cancer. EXPERIMENTAL
DESIGN: An unbiased systematic analysis was performed in multiple independent datasets to define genes predictive of complete pathologic response (pCR) following treatment with neoadjuvant chemotherapy. These genes were interrogated across estrogen receptor (ER)-positive and ER-negative breast cancer and those in common across three different treatment regimens were analyzed for optimal predictive power. Subsequent validation was performed on independent cohorts by gene expression and IHC analyses.
RESULTS: Genes that were highly associated with the response to neoadjuvant chemotherapy in breast cancer were readily defined using a computational method ranking individual genes by their respective ROC. Such predictive genes of the response to taxane-associated therapies were strongly enriched for cell-cycle control processes in both ER-positive and ER-negative breast cancer and correlated with pCR. However, other genes that were specifically associated with residual disease were also identified under other treatment conditions. Using the intersection between treatment groups, nine genes were identified that harbored strong predictive power in multiple contexts and validation cohort. In particular, the nuclear oncogene DEK was strongly associated with pCR, whereas the cell surface protein BCAM was strongly associated with residual disease. By IHC staining, these markers exhibited potent predictive power that remained significant in multivariate analysis.
CONCLUSION: Systematic computational approaches can define key genes that will be able to predict the response to chemotherapy across multiple treatment modalities yielding a small collection of biomarkers that can be readily deployed by IHC analyses. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25047707      PMCID: PMC5286972          DOI: 10.1158/1078-0432.CCR-14-0885

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  37 in total

1.  Directed therapy of subtypes of triple-negative breast cancer.

Authors:  Lisa A Carey
Journal:  Oncologist       Date:  2011

2.  Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen.

Authors:  Soonmyung Paik
Journal:  Oncologist       Date:  2007-06

Review 3.  Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer.

Authors:  Rachel A Freedman; Eric P Winer
Journal:  Breast       Date:  2010-01-19       Impact factor: 4.380

4.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Authors:  Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Alexey Manikhas; Ana Lluch; Sergey Tjulandin; Milvia Zambetti; Federico Vazquez; Mikhail Byakhow; Mikhail Lichinitser; Miguel Angel Climent; Eva Ciruelos; Belén Ojeda; Mauro Mansutti; Alla Bozhok; Roberta Baronio; Andrea Feyereislova; Claire Barton; Pinuccia Valagussa; Jose Baselga
Journal:  Lancet       Date:  2010-01-30       Impact factor: 79.321

Review 5.  Proliferation: the most prominent predictor of clinical outcome in breast cancer.

Authors:  Christine Desmedt; Christos Sotiriou
Journal:  Cell Cycle       Date:  2006-10-01       Impact factor: 4.534

Review 6.  Neoadjuvant treatments for triple-negative breast cancer (TNBC).

Authors:  G von Minckwitz; M Martin
Journal:  Ann Oncol       Date:  2012-08       Impact factor: 32.976

7.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

Authors:  Scott L Carter; Aron C Eklund; Isaac S Kohane; Lyndsay N Harris; Zoltan Szallasi
Journal:  Nat Genet       Date:  2006-08-20       Impact factor: 38.330

Review 8.  Stacking the DEK: from chromatin topology to cancer stem cells.

Authors:  Lisa M Privette Vinnedge; Ferdinand Kappes; Nicolas Nassar; Susanne I Wells
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

Review 9.  Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future.

Authors:  Simon P Gampenrieder; Gabriel Rinnerthaler; Richard Greil
Journal:  J Oncol       Date:  2013-08-20       Impact factor: 4.375

10.  Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

Authors:  Mitch Dowsett; Ivana Sestak; Elena Lopez-Knowles; Kalvinder Sidhu; Anita K Dunbier; J Wayne Cowens; Sean Ferree; James Storhoff; Carl Schaper; Jack Cuzick
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

View more
  8 in total

1.  The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.

Authors:  J Martinez-Useros; I Moreno; M J Fernandez-Aceñero; M Rodriguez-Remirez; A Borrero-Palacios; A Cebrian; T Gomez Del Pulgar; L Del Puerto-Nevado; W Li; A Puime-Otin; N Perez; M S Soengas; J Garcia-Foncillas
Journal:  BMC Cancer       Date:  2018-02-06       Impact factor: 4.430

Review 2.  Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.

Authors:  Erik S Knudsen; Steven C Pruitt; Pamela A Hershberger; Agnieszka K Witkiewicz; David W Goodrich
Journal:  Trends Cancer       Date:  2019-04-30

3.  Potential of DEK proto-oncogene as a prognostic biomarker for colorectal cancer: An evidence-based review.

Authors:  Muhammad Habiburrahman; Muhammad Prasetio Wardoyo; Stefanus Sutopo; Nur Rahadiani
Journal:  Mol Clin Oncol       Date:  2022-05-26

4.  A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer.

Authors:  Masanori Oshi; Shipra Gandhi; Fernando A Angarita; Tae Hee Kim; Yoshihisa Tokumaru; Li Yan; Ryusei Matsuyama; Itaru Endo; Kazuaki Takabe
Journal:  Am J Cancer Res       Date:  2021-07-15       Impact factor: 5.942

5.  DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.

Authors:  Javier Martinez-Useros; Maria Rodriguez-Remirez; Aurea Borrero-Palacios; Irene Moreno; Arancha Cebrian; Teresa Gomez del Pulgar; Laura del Puerto-Nevado; Ricardo Vega-Bravo; Alberto Puime-Otin; Nuria Perez; Sandra Zazo; Clara Senin; Maria J Fernandez-Aceñero; Maria S Soengas; Federico Rojo; Jesus Garcia-Foncillas
Journal:  BMC Cancer       Date:  2014-12-16       Impact factor: 4.430

6.  LncRNA Profile Study Reveals a Three-LncRNA Signature Associated With the Pathological Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Ying Zeng; Guo Wang; Cheng-Fang Zhou; Hai-Bo Zhang; Hong Sun; Wei Zhang; Hong-Hao Zhou; Rong Liu; Yuan-Shan Zhu
Journal:  Front Pharmacol       Date:  2019-05-28       Impact factor: 5.810

7.  G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer.

Authors:  Masanori Oshi; Hideo Takahashi; Yoshihisa Tokumaru; Li Yan; Omar M Rashid; Ryusei Matsuyama; Itaru Endo; Kazuaki Takabe
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923

8.  Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.

Authors:  Yanding Zhao; Evelien Schaafsma; Chao Cheng
Journal:  Cancer Med       Date:  2020-07-21       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.